Press Releases

 
Press Releases
  Date Title View
May 4, 2004
BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for the ...
Mar 29, 2004
BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for t...
Mar 29, 2004
In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated Balance Sheets" financial table should read "12,762" rather than "2,762," as incorrectly transmitted...
Mar 25, 2004
BERKELEY, Calif., March 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, will hold an earnings conference call ...
Mar 8, 2004
BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit Committee. With Dr. Gilbert's addition, Dynavax's Board of Directors increased to seven members....
Mar 4, 2004
BERKELEY, Calif., March 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of D. Kevin Kwok, Pharm.D., to the position of vice president and chief business officer."We are excited to have Kevin join our team," said Dino Dina, M.D., president and chief executive officer of Dynavax. "...
Feb 25, 2004
BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the start of a multi-site, phase II/III clinical trial to evaluate the safety and efficacy of its ragweed allergy immunotherapy product candidate, AIC. The two-year study will enroll 462 subjects at 30 allergy clinics throu...
Feb 24, 2004
BERKELEY, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that the underwriters of its previously announced initial public offering of 6,000,000 shares of common stock have fully exercised their over-allotment option and acquired 900,000 common shares to cover over-allotments. To...
Feb 19, 2004
BERKELEY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it has priced its initial public offering of 6,000,000 shares of its common stock at $7.50 per share, below the estimated range. Dynavax Technologies Corporation discovers, develops, and intends to commercial...
Feb 5, 2004
Berkeley, CA - February 5, 2004 - Dynavax Technologies Corporation announced today that it has entered into an agreement with UCB Pharma, the pharmaceuticals division of UCB Group, a publicly traded multi-national company based in Brussels, Belgium, in which Dynavax licensed the technology, know-how and preclinical and clinical data related to i...
FirstPrevious
...
41
NextLast
= add release to Briefcase